Vector constructs

Details Vector constructs Vector constructs

2006-09-19

2006-09-19

Guzo, David (Department: 1636)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S320100, C435S455000, C435S456000, C435S235100, C435S366000, C424S093100, C424S093200, C424S093600, C536S063000, C536S023200, C536S023500, C536S023720, C536S024100

Reexamination Certificate

active

07109029

ABSTRACT:
The present invention provides novel viral vectors and methods useful for the minimization of leaky gene expression, and, in particular, of nonspecific transcriptional read-through of genes. Such constructs may be obtained by the insertion of an insulating sequence into a vector construct, such as for example a termination signal sequence upstream of the transcription initiation site of the respective transcription unit.

REFERENCES:
patent: 5672344 (1997-09-01), Kelley et al.
patent: 5677178 (1997-10-01), McCormick
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5707618 (1998-01-01), Armentano et al.
patent: 5830686 (1998-11-01), Henderson
patent: 5837511 (1998-11-01), Falck-Pedersen et al.
patent: 5871726 (1999-02-01), Henderson et al.
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6013638 (2000-01-01), Crystal et al.
patent: 6057299 (2000-05-01), Henderson
patent: 6136792 (2000-10-01), Henderson
patent: 6197293 (2001-03-01), Henderson et al.
patent: 6254862 (2001-07-01), Little et al.
patent: 6271207 (2001-08-01), Cristiano et al.
patent: 6297219 (2001-10-01), Nabel et al.
patent: 6420170 (2002-07-01), Perricaudet et al.
patent: 6432700 (2002-08-01), Henderson et al.
patent: 6436394 (2002-08-01), Henderson et al.
patent: 6458586 (2002-10-01), Tikoo et al.
patent: 6495130 (2002-12-01), Henderson et al.
patent: 6686196 (2004-02-01), Lieber et al.
patent: 2001/0006633 (2001-07-01), Kirn
patent: 2001/0046965 (2001-11-01), Ayares et al.
patent: 2004/0241857 (2004-12-01), Henderson et al.
patent: WO 92/03563 (1992-03-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 95/19434 (1995-07-01), None
patent: WO 96/34969 (1996-11-01), None
patent: WO 97/01358 (1997-01-01), None
patent: WO 97/04805 (1997-02-01), None
patent: WO 97/48277 (1997-12-01), None
patent: WO 98/13508 (1998-04-01), None
patent: WO 98/272007 (1998-06-01), None
patent: WO 98/35028 (1998-08-01), None
patent: WO 98/39464 (1998-09-01), None
patent: WO 98/39465 (1998-09-01), None
patent: WO 98/39466 (1998-09-01), None
patent: WO 98/39467 (1998-09-01), None
patent: WO 99/06576 (1999-02-01), None
patent: WO 99/28469 (1999-06-01), None
patent: WO 99/55831 (1999-11-01), None
patent: WO 99/59604 (1999-11-01), None
patent: WO 00/03029 (2000-01-01), None
patent: WO 00/15820 (2000-03-01), None
patent: WO 00/22124 (2000-04-01), None
patent: WO 00/29599 (2000-05-01), None
patent: WO 00/31286 (2000-06-01), None
patent: WO 00/39319 (2000-06-01), None
patent: WO 00/46355 (2000-08-01), None
patent: WO 00/47768 (2000-08-01), None
patent: WO 00/56909 (2000-09-01), None
patent: WO 00/67576 (2000-11-01), None
patent: WO 00/70071 (2000-11-01), None
patent: WO 01/02540 (2001-01-01), None
patent: WO 01/04282 (2001-01-01), None
patent: WO 01/04334 (2001-01-01), None
patent: WO 01/23004 (2001-04-01), None
patent: WO 01/36650 (2001-05-01), None
patent: WO 01/72341 (2001-10-01), None
patent: WO 01/73093 (2001-10-01), None
patent: WO 01/83796 (2001-11-01), None
patent: WO 02/068627 (2002-09-01), None
U.S. Appl. No. 10/081,969, filed Feb. 22, 2002, Ennist et al.
Adams, et al., “Transcriptional Control by E2F,” Seminars in Cancer Biology, 6:99-108 (1995).
Alemany, et al., “Replicative Adenoviruses for Cancer Therapy,” Nature Biotechnology, 18:723-727 (Jul. 2000).
Angelichio, et al., “Comparison of Several Promoters and Polyadenylation Signals for Use in Heterologous Gene Expression in Cultured Drosophila Cells,” Nucleic Acids Research, 19(18):5037-5043 (1991).
Armitage, J., “Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor,” Blood, 92(12):4491-4508 (Dec. 15, 1998).
Babiss, et al., “Cellular Promoters Incorporated into the Adenovirus Genome: Effects of Viral Regulatory Elements on Transcription Rates and Cell Specificity of Albumin and Beta-Globin Promoters,” Molecular and Cellular Biology, 6(11):3798-3806 (Nov. 1986).
Bergsland, et al., “Shedding Old Paradigms: Developing Viruses to Treat Cancer,” Journal of Clinical Oncology, 20(9):2220-2222 (May 1, 2002).
Bert, et al., “Generation of an Improved Luciferase Reporter Gene Plasmid that Employs a Novel Mechanism for High-Copy Replication,” Plasmid, 44:173-182 (Sep. 2000).
Black, et al., “Regulation of E2F: A Family of Transcription Factors Involved in Proliferation Control,” Gene, 237:281-302 (1999).
Bristol, et al., “GM-CSF Containing Oncolytic Adenoviruses for the Treatment of Cancer,” Abstract No. P2, presented at The 10th Annual Meeting of the European Society for Gene Therapy. Antibes. France. Oct. 13-16, 2002.
Bristol, et al., “GM-CSF Mediated Stimulation of Innate Anti-tumor Responses,” poster presented at the Keystone Symposia, Basic Aspects of Tumor Immunology, Feb. 17-23, 2003.
Bristol, et al., “GM-CSF Containing Oncolytic Adenoviruses for the Treatment of Cancer,” poster presented at The 10th Annual Meeting of the European Society for Gene Therapy, Antibes, France, Oct. 13-16, 2002.
Bristol, et al., “In Vivo Anti-Tumor Activity of Oncolytic Adenoviruses that Express GM-CSF in Xenograft Tumor Models,” American Society for Gene Therapy, 5th Annual Meeting, Jun. 5-9, 2002; poster presented Jun. 6, 2002.
Bristol, et al., “In Vivo Anti-Tumor Activity of Oncolytic Adenoviruses that Expresses GM-CSF in Xenograft Tumor Models,” Molecular Therapy, 5(5):abstract No. 311 (May 2002).
Bruder, et al., “Nuclear Factor Ef-1A Binds to the Adenovirus E1A Core Enhncer Element and to Other Transcriptional Control Regions,” Molecular and Cellular Biology, 9(11):5143-5153 (Nov. 1989).
Bryan, et al., “Evidence for an Alternative Mechanism for Maintaining Telomere Length in Human Tumors and Tumor-derived Cell Lines,” Nature Medicine, 3(11):1271-1274 (Nov. 1997).
Chang, et al., “Immunogenetic Therapy of Human Melanoma Utilizing Autologous Tumor Cells Transduced to Secrete Granulocyte-Macrophage Colony-Stimulating Factor,” Human Gene Therapy, 11:839-850 (Apr. 10, 2000).
Chao, et al., “Assembly of the Cleavage and Polyadenylation Apparatus Requires About 10 Seconds In Vivo and Is Faster for Strong Than for Weak Poly(A) Sites,” Molecular and Cellular Biology, 19(8):5588-5600 (Aug. 1999).
Chen, et al., “Antiangiogenic Gene Therapy for Cancer via Systemic Administration of Adenoviral Vectors Expressing Secretable Endostatin,” Human Gene Therapy, 11:1983-1996 (Sep. 20, 2000).
Chen, et al., “Cleavage Site Determinants in the Mammalian Polyadenylation Signal,” Nucleic Acids Research, 23(14):2614-2620 (1995).
Chia, et al., “A Novel Conditionally Oncolytic Adenovirus for the Treatment of Nasopharyngeal Carcinoma (NPC),” Proceedings of the American Associaton for Cancer Research, 43:1098-1099, abstract No. 5441 (Mar. 2002).
Chiocca, E., “Oncolytic Viruses,” Nature, 2:938-950 (Dec. 2002).
Christ, et al., “Modulation of the Inflammatory Properties and Hepatotoxicity of Recombinant Adenovirus Vectors by the Viral E4 Gene Products,” Human Gene Therapy, 11:415-427 (Feb. 10, 2000).
Colgan, et al., “Mechanism and Regulation of mRNA Polyadenylation,” Genes and Development, 11:2755-2766 (1997).
Curiel, et al., “Strategies to Improve the Therapeutic Utility of Conditionally Replicative Adenoviruses (CRAds) for Cancer Therapy,” Proceedings of the American Association for Cancer Research, 43:662, abstract No. 3287 (Mar. 2002).
Demers, et al., “Antitumor Efficacy and Replication of an Oncolytic Adenovirus, 01/PEME, in Tumor Tissue Following Intravenous Administration,” Proceedings of the American Association for Caner Research, 43:663, abstract No. 3291 (Mar. 2002).
Denome, et al., “Patterns of Polyadenylation Site Selection in Gene Constructs Containing Multiple Polyadenylation Signals,” Molecular and Cellular Biology, 8(11):4829-4839 (Nov. 1988).
DeWeese, et al., &#x

Affiliated with

Also associated with

Rating

Vector constructs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vector constructs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vector constructs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3582324